Gilead Sciences News

A A A' Product Pipeline Review A A A' H2 2011 - a new company profile report on companiesandmarkets.com Gilead Sciences, Inc.

Boston-based MFS Investment Management has over $265 billion in assets under management, including over $90 billion in 13-F assets per its latest Q4 filing on Friday.

Since I first promoted Gilead Sciences in my bullish article here , the stock has taken off like a rocket and gained 40.8%, beating the Dow Jones more than 6x over.

NEW YORK &#8212 A Morgan Stanley analyst said Friday that he believes shares of biotech drugmakers Gilead Sciences, Biogen Idec and Celgene will do well in 2012 because all three companies are poised to report encouraging results for important drug candidates.

Aptalis Pharmaceutical Technologies Announces FDA Approval of NDA for Oral Powder Formulation of VireadA , Co-Developed With Gilead Sciences, Inc.

Insiders reported on Thursday that they bought and sold stock in over 350 separate transactions in over 170 different companies.

InterMune, Inc. A reported a drop to a loss in the fourth quarter driven by higher costs.A Reported a loss of $44.5 million in the quarter.

With the Dow well above the 12,000 mark again, but the threat of a recession still present, it would do investors well to consider the impact a renewed downturn might have on our portfolios.

Get news bulletins by email>> China's Jan. trade surplus wider than expected, but exports shrink 0.5% from last year That's a nagging question for investors, who have watched Vertex's once-bright star fade as the shares of rival hepatitis C-drug developers supernovae.

FOSTER CITY, Calif. -- -- Gilead Sciences, Inc. today announced that John F. Milligan, PhD, Gilead's President and Chief Operating Officer, will be participating in "fireside chat" forums at two upcoming investor conferences taking place in New York.

UC San Diego has released the names of five alumni and supporters of the university to be honored at its annual Alumni Celebration on June 2 as part of its Alumni Weekend from Mary 31 through June 3. Dr.

InterMune, Inc. A will unveil its latest earnings on Thursday, February 9, 2012.A The average estimate of analysts is for a loss of 71 cents per share, a wider loss from the year earlier quarter net loss of 39 cents.

Following bullish earnings, Karee Venema of Schaeffer's Research writes that call buyers are piling in to one biopharmaceutical stock that has soared to three-year highs in just the last 60 days.

Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.

The First Trust NYSE Arca Biotechnology Index Fund ETF is seeing unusually high volume in afternoon trading Wednesday, with over 144,000 shares traded versus three month average volume of about 129,000. Shares of FBT were down about 1.2% on the day.

Five distinguished alumni and supporters of the University of California, San Diego will be honored at the university's annual Alumni Celebration to be hosted June 2. This year's scroll of honorees range from a game-changing scientist who has created innovative drugs, to an angel investor who has been the driving force for the Rady School of ... (more)

Las Vegas Sands : After investing his own money to help revive the company, Sheldon Adelson, CEO and chairman of Las Vegas Sands , is reaping the rewards of the casino company's turnaround, says the Wall Street Journal The shares closed at $51.48, down $0.43 or 0.83% on the day.

In the following article I will discuss five companies that are good money making ideas based on fundamentals, profitability and/or dividend payout measurements.

Equities research analysts at ThinkEquity increased their price target on shares of Gilead Sciences from $50.00 to $61.00 in a research note issued to investors on Monday.

Micron Technology Inc. : After the death of Micron CEO Steve Appleton, Oppenheimer believes the company has a deep executive bench and several positive catalysts this year.